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Abstract
Background: Over 200 million individuals worldwide are infected with Schistosoma species, with over half of
infections occurring in children. Many children experience first infections early in life and this impacts their growth
and development; however praziquantel (PZQ), the drug used worldwide for the treatment of schistosomiasis, only
has regulatory approval among adults and children over the age of four, although it is frequently used “off label” in
endemic settings. Furthermore, pharmacokinetic/pharmacodynamics (PK/PD) evidence suggests the standard PZQ
dose of 40 mg/kg is insufficient in preschool-aged children (PSAC). Our goal is to understand the best approaches
to optimising the treatment of PSAC with intestinal schistosomiasis.
Methods: We will conduct a randomised, controlled phase II trial in a Schistosoma mansoni endemic region of
Uganda and a Schistosoma japonicum endemic region of the Philippines. Six hundred children, 300 in each setting,
aged 12–47 months with Schistosoma infection will be randomised in a 1:1:1:1 ratio to receive either (1) 40 mg/kg
PZQ at baseline and placebo at 6 months, (2) 40 mg/kg PZQ at baseline and 40 mg/kg PZQ at 6 months, (3) 80 mg/
kg PZQ at baseline and placebo at 6 months, or (4) 80 mg/kg PZQ at baseline and 80 mg/kg PZQ at 6 months.
Following baseline treatment, children will be followed up for 12 months. The co-primary outcomes will be cure
rate and egg reduction rate at 4 weeks. Secondary outcomes include drug efficacy assessed by novel antigenic
endpoints at 4 weeks, actively collected adverse events and toxicity for 12 h post-treatment, morbidity and
nutritional outcomes at 6 and 12 months, biomarkers of inflammation and environmental enteropathy and PZQ PK/
PD parameters.
Discussion: The trial will provide valuable information on the safety and efficacy of the 80 mg/kg PZQ dose in
PSAC, and on the impact of six-monthly versus annual treatment, in this vulnerable age group.
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Background
Schistosomiasis is a water-borne, disabling parasitic dis-
ease affecting over 200 million individuals globally and
accounting for over 1.4 million disability-adjusted life
years (DALYS) [1]. There are three main species of
tissue-invasive parasitic trematodes of the genus Schisto-
soma (S.), responsible for causing schistosomiasis-related
morbidity in different geographic areas: S. mansoni in
sub-Saharan Africa (SSA) and South America, S. haema-
tobium in SSA and S. japonicum in Asia [2]. A signifi-
cant proportion of the global burden of schistosomiasis
comprises key morbidities that disproportionally affect
children [3]. Specifically, growth and development re-
lated disabilities attributed to schistosomiasis include
undernutrition, linear growth stunting [4], anaemia [5]
and cognitive impairment [6]. Importantly, young chil-
dren are most vulnerable to these morbidities given this
period coincides with peak velocities of somatic and
brain growth, with the highest global prevalence of an-
aemia, linear growth stunting, decreased aerobic capacity
[7] and undernutrition occurring in this age group
worldwide [8, 9]. Despite this vulnerability and likely in-
creased risk of morbidity due to schistosomiasis,
preschool-aged children (PSAC) are excluded from pre-
ventive chemotherapy campaigns, which represent the
primary approach for reducing infections in endemic re-
gions [10, 11]. Few if any studies have evaluated the ef-
fect of treatment on these key indicators of early
childhood well-being.
The persistent treatment gap among PSAC is partially
driven by the fact that praziquantel (PZQ), the recom-
mended treatment against all forms of schistosomiasis,
has regulatory approval only for children aged 4 years
and older [12]. National control strategies often focus on
school-based treatment, with community treatment rec-
ommended only in highly endemic areas. The World
Health Organization (WHO) recommends that PZQ at a
dose of 40 mg/kg be used to treat schistosomiasis infec-
tion in PSAC [13]. However, this recommended dose re-
lied predominantly on differences in cure and egg
reduction rates at different doses from a relatively small
number of studies. The 40-mg/kg dose was also based
on extrapolating from the relatively few pharmacoki-
netic/pharmacodynamics (PK/PD) studies of healthy
adults as well as adults with varying degrees of liver fail-
ure. Despite the known flaws of this approach, including
evidence from quantitative pharmacological methods
that an extrapolation approach does not achieve accurate
paediatric dosing, this continues to define dosing
regimens for children [14, 15]. This is of significant con-
cern given the many differences in drug absorption, me-
tabolism and distribution among children compared to
adults [16]. Weight alone does not capture age-
dependent nonlinearities in drug metabolism [14]. Spe-
cifically, body weight-normalised drug clearance in chil-
dren exceeds that of adults for many drugs [16],
suggesting children may require a higher dose per unit
of bodyweight.
A recent PK/PD study comparing 40 mg/kg versus 60
mg/kg of PZQ among children aged 3–8 years living in a
S. mansoni endemic region of Uganda found that the
total PZQ area under the concentration time curve
(AUC) was a significant predictor of both cure rate and
egg reduction rate, while administered dose was not a
significant predictor [17]. Subsequent modelling sug-
gested that doses much higher than 40mg/kg will be ne-
cessary to achieve cure rates of 85% as recommended by
the WHO, particularly among younger children [17].
Specifically, it is likely that 80 mg/kg is necessary to
achieve recommended cure rates.
Through the PZQ in preschoolers (PIP) trial, we will
address the significant gaps with respect to our under-
standing of the best approaches to optimise treatment of
PSAC with intestinal schistosomiasis including both op-
timal dose (40 vs 80 mg/kg) and frequency of dosing
(once or twice annually).
Methods
The PIP trial protocol is reported following Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines (Additional file 1) [18].
Trial objectives
The primary objective of this trial is to compare para-
sitological cure and egg reduction rate of PZQ at a dose
of 80 mg/kg versus PZQ at a dose of 40 mg/kg, among
children aged 12–47months. Secondary objectives in-
clude the following:
 To assess the safety and efficacy and PK/PD of PZQ
administered at 80 mg/kg versus 40 mg/kg
 To evaluate the PK/PD of both PZQ enantiomers
(R/S) given the concern that this has varied in
studies of S. mansoni
 To expand PD endpoints for drug efficacy to include
antigen tests (circulating anodic antigen; CAA) that
accurately capture residual worm burden, and assess
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the impact of 80 mg/kg versus 40 mg/kg PZQ on
these endpoints
 To assess the impact of 80 mg/kg PZQ versus 40
mg/kg PZQ and of annual versus biannual PZQ
treatment on key measures of growth and morbidity
 To evaluate the mechanisms mediating the effect of
varying PZQ treatment doses and frequencies on
growth and schistosomiasis-related morbidity (nutri-
tional status, anaemia)
 To evaluate the mechanistic role of environmental
enteric dysfunction (EED) in the pathogenesis of
schistosomiasis related morbidities
 To explore immune responses to S. mansoni
infection and treatment
 To determine the prevalence and the pattern of
schistosomiasis-related morbidity as determined by
ultrasound scan
Trial design
This will be a two-centre individually randomised quasi-
double blinded placebo-controlled trial with four parallel
arms (Fig. 1). Children aged 12–47months will be en-
rolled and followed up at 4 weeks, 6 months and 12
months post-baseline. All participants will receive PZQ
(at either 80 mg/kg or 40mg/kg) at baseline. Half of the
cohort will receive an additional PZQ dose (at the same
dose as they were given at baseline) at 6 months and half
will receive placebo at 6 months. Parasitological end-
points will be measured at 4 weeks, morbidity endpoints
at 6 and 12months. The schedule of participant enrol-
ment, interventions and assessment is shown in Fig. 2.
Trial settings
The trial will be conducted in a S. mansoni endemic
setting in Uganda and a S. japonicum endemic set-
ting in the Philippines. In Uganda, participants will
be recruited from villages located on the shores of
Lake Albert in Buliisa district in western Uganda. A
recent study in these villages found S. mansoni
prevalence of 57% by Kato-Katz among children
aged 3–5 years [19]. The general health of children
is poor, and there are high rates of undernutrition
with approximately 38% stunted and 16% under-
weight [20]. The Uganda Ministry of Health Vector
Control Division has a long-established field station,
the Kabatereine Schistosomiasis Research Camp, lo-
cated at Bugoigo village, which has recently been
updated to accommodate the facilities necessary to
conduct study procedures. In the Philippines, partic-
ipants will be recruited from rice farming villages in
Leyte district, with further study procedures con-
ducted at the field laboratory in Palo, Leyte. In a
community survey of these villages conducted in
May 2016, S. japonicum infection prevalence among
1–4-year-olds was 42%. In addition, 67% of children
were stunted (height-for-age z-score < − 2) and 15%
were wasted (BMI-for-age z-score < − 2) [21]. In
both study settings, the population size per village
ranges from approximately 600 to 1900 individuals,
and approximately 10% of the population are aged
under 4 years. It is anticipated that participants will
be recruited from approximately 15–20 villages
across the two study settings to achieve the planned
sample size.
Fig. 1 Schematic of study design
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Screening and eligibility
Fishing and rice farming communities where schisto-
somiasis is endemic will be approached through
community-wide information meetings. Prior to these,
the village chiefs and leaders will be contacted to inform
them about the project and obtain permission to hold
meetings. These meetings will be announced publicly
with flyers distributed by community mobilisers who will
be in charge of contacting interested parents after the
information sessions have taken place.
Screening will take place in two phases. The first phase
will comprise circulating cathodic antigen (CCA) testing
of urine samples [22, 23] from potential participants in
the villages by field staff after informed consent for this
initial screening activity has been obtained. Children
with a positive CCA test will be considered positive for
Schistosoma infection and eligible for potential enrol-
ment. Parents will then be given three cups to provide
stool samples collected on different days to ascertain
egg-patent infection and quantify intensity of infection
at baseline.
The second screening phase will take place at the field
laboratories (in Bugoigo for Uganda, and Palo for the
Philippines) to ensure other eligibility criteria are met
Fig. 2 PIP trial schedule of enrolment, interventions and assessments
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prior to enrollment. Activities related to the second
phase of screening and the main trial procedures will be
reviewed and informed consent obtained (Supplemental
Information). The second phase of screening will include
an assessment of nutritional status, laboratory studies
and physical examination and history to rule out condi-
tions that might deem a child ineligible.
Inclusion criteria will be as follows:
 S. mansoni infection of any intensity as determined
by Kato-Katz
 Otherwise healthy as determined by history and
physical examination conducted by the study
physician at the second stage screening
 Age 12–47months inclusive
 Parental consent to participate
Exclusion criteria will be as follows:
 Parental inability to provide informed consent
 Significant disease/illness as determined by history
or physical exam. This includes a severe acute illness
or chronic disease as defined by greater than 3
months’ duration and significantly impacting a
child’s daily activities.
 Grade 3 or higher laboratory abnormality of blood
urea nitrogen (BUN), creatinine, bilirubin, white
blood cell count, or platelet count will warrant
exclusion. Grade 2 or higher abnormality of alanine
aminotransferase (ALT) or aspartate
aminotransferase (AST) will warrant exclusion.
Children with severe anaemia as defined by
haemoglobin less than 7.0 g/dl will be excluded.
 Severe wasting as defined by weight-for-height z-
score < − 3
 Exposure to immuno-modulatory therapeutics such
as steroids e.g. dexamethasone, prednisone and other
medications such as chloroquine
 Confirmed diagnosis of ocular cysticercosis
Information and consent
Information sheets will be provided to interested par-
ents/guardians of potential participants. Information
sheets will be available in English and the main local lan-
guages. Parents will be provided with an oral and written
explanation of the study to ensure that information is
accessible. The informed consent process for the first
phase of screening will be conducted by good clinical
practice (GCP) certified community workers. The in-
formed consent process for the second phase of screen-
ing will be conducted by project staff trained in GCP
and who speak the local language. Consent will also be
obtained for use of stored samples. Witnessed consent
will be available to parents or guardians who are non-
literate.
Withdrawal of participants
At all stages, it will be made clear to parents of study
participants that they may voluntarily withdraw consent
for their child’s participation in the study at any time,
without penalty or loss of benefits, and without needing
to provide any reason or explanation. The study team
may also withdraw a participant from receiving the study
product for any reason, but follow-up safety evaluations
will continue to be conducted, if the parent agrees. Any
child experiencing a severe allergic or anaphylactic reac-
tion to any dose of PZQ given during the study will be
withdrawn by the study team.
Interventions
Participants will be randomised to receive one of the fol-
lowing four interventions:
Group 1
 At baseline, 40 mg/kg PZQ followed by placebo 3 h
later
 At 6 months post-baseline, placebo followed by pla-
cebo 3 h later
Group 2
 At baseline, 40 mg/kg PZQ followed by placebo 3 h
later
 At 6 months post-baseline, 40 mg/kg PZQ followed
by placebo 3 h later
Group 3
 At baseline, 80 mg/kg PZQ split as 40 mg/kg and 40
mg/kg 3 h later
 At 6 months post-baseline, placebo followed by pla-
cebo 3 h later
Group 4
 At baseline, 80 mg/kg PZQ split as 40 mg/kg and 40
mg/kg 3 h later
 At 6 months post-baseline, 80 mg/kg PZQ split as
40 mg/kg and 40 mg/kg 3 h later
Randomisation and masking
Placebo consisting of tablets matched for size, shape and
colour with the PZQ tablets, will be prepared at Tedor
Pharma, Cumberland, RI, USA and shipped to independ-
ent pharmacies in Entebbe, Uganda and Manila, The
Philippines. Prior to first enrolment, a randomisation
list, stratified by study site, indicating a randomisation
number and trial arm allocation, will be prepared by the
trial statistician using a random number generator with
randomly permuted block sizes. The randomisation list
will be shared with the independent pharmacists, who
will be otherwise uninvolved in the trial. In each coun-
try, the pharmacist will pre-fill two vials per child for
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each study visit’s two doses based on their randomisation
group, i.e. two doses at baseline and two doses at 6
months. Vials will be labelled with the assigned study
number, according to the randomisation list. Following
enrolment, children will be sequentially assigned to the
next study identification number. Following baseline an-
thropometry, blood and urine lactulose:mannitol sam-
pling, study staff will open the first vial labelled with that
randomisation number and dispense the study product
contained in the vial. This will be done according to
weight, with tablets crushed and given with juice. Suffi-
cient tablets will be included in each vial to allow for the
maximum expected weight of a participant and repeat
dosing (once only) in the event of vomiting within one
hour of dosing. This will be a quasi-double blind approach
as we will not be able to fully mask taste for participants.
Outcomes
The trial will have two co-primary outcomes: (1) cure
rate and (2) egg reduction rate at 4 weeks after baseline
treatment. Cure rate will be defined as the proportion of
participants who are Kao-Katz negative on all samples at
4 weeks. Egg reduction rate will be defined as the per-
centage reduction in egg burden from baseline to 4
weeks post treatment as assessed by Kato-Katz.
The secondary outcomes of the trial will be as follows:
 Drug efficacy by novel antigenic endpoint (CCA and
CAA) [24] at 4 weeks
 Adverse events in children for 12 h following PZQ
treatment at baseline and at 6 months
 Bone marrow, renal and liver toxicity for 12 h
following PZQ treatment at baseline
 Iron status, haemoglobin, growth and nutrition at 6
and 12 months
 Biomarkers of inflammation and environmental enteric
dysfunction (EED): faecal calprotectin and occult blood
[25], serum endotoxin, serum endotoxin core antibody
and pro-inflammatory cytokines at 6 and 12months;
urine lactulose:mannitol ratio at 12months
 The PZQ PK/PD parameters including AUC for 12
h following baseline dosing, among a random
sample of half the children
 Immune responses to S. mansoni infection and
treatment at 4 weeks, 6 months and 12 months,
among a random sample of half the children
 Prevalence and the pattern of schistosomiasis-related
morbidity as determined by ultrasound scan at 6
and 12 months.
Study procedures and baseline assessments: enrolment
visit
Children meeting eligibility criteria will be admitted to
the Bugoigo and Palo field stations for a period of up to
24 h for the enrolment visit. This visit will comprise
baseline (pre-intervention) assessment of morbidity, an-
thropometry and nutrition outcome measures, adminis-
tration of the baseline intervention, and PK/PD (for a
random sample of half the children), adverse event and
safety data collection following baseline intervention.
Stool samples provided at screening will be used to de-
termine baseline Schistosoma egg burden by microscopy.
Faecal calprotectin and occult blood will be performed
at the baseline visit. Blood samples (5 ml) will be taken
for baseline assessment of complete blood count, and
renal and liver function, with serum used for assessment
of morbidity (iron status, EED biomarkers, measures of
inflammation including pro-inflammatory cytokines and
C-reactive protein (CRP)). A small blood drawing can-
nula will be placed to minimise the number of times
children have a needle inserted. Rapid HIV and malaria
testing will be administered following standard
protocols.
A lactulose:mannitol test [26] will be administered to
test gut permeability and absorptive capacity: following a
30-min fast (breast feeding will continue), lactulose-
mannitol solution containing 250 mg/ml lactulose and
50mg/ml mannitol in purified water will be given to
study participants orally at a dose of 2 ml/kg up to a
maximum of 20 ml. A urine bag will be strapped and
urine will be collected for 2 h afterwards. Once collected,
an aliquot of 2 ml urine will be stored between 2 and 8
°C having added 2 drops of chlorhexidine.
Following blood collection and completion of the
urine lactulose:mannitol test, a meal of local foods will
be given, and the study interventions will be dispensed
as described under “Randomisation and masking”. After
receiving the first study intervention, all children will be
clinically monitored for 12 h and any adverse events will
be recorded, with supportive treatment given if neces-
sary. Data on anticipated adverse events (headache, mal-
aise, drowsiness, abdominal pain, nausea, vomiting,
shortness of breath, dizziness, rash, urticaria, fever) will
be collected actively, while any unanticipated adverse
events will also be captured as part of the clinical moni-
toring process. Bone marrow, renal and liver toxicity will
be assessed in a final blood collection (3 ml) at 12 h post
dosing. After administration of the second dose of the
study product, children will undergo ultrasound scan to
determine baseline presence or absence of any
schistosomiasis-related liver pathology, with the Niamey
Protocol used to grade severity of disease [27].
Participants will be randomly divided into two equally
sized groups: one group (N = 150 at each site) will
undergo additional blood sampling for PK assessment
(four blood draws total over a 12-h period using the in-
dwelling cannula, maximum total blood volume 5ml)
while the other group (N = 150 in each setting) will have
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7 ml blood taken for assessment of immune responses to
Schistosoma infection and treatment. At discharge, any
child found to be infected with soil-transmitted hel-
minths at enrolment will be treated with albendazole.
Study procedures and outcome assessments: 4-week visit
The primary outcomes will be assessed at this visit,
which will be conducted 4 weeks after the enrolment
visit. Field workers will visit participants in their villages
and collect stool samples on at least two consecutive
days for assessment of Schistosoma egg burden by Kato-
Katz. They will also collect urine samples for measure-
ment of CCA and CAA. Children who were randomly
selected at baseline for the assessment of immune re-
sponses to Schistosoma infection and treatment will have
a repeat blood sample (7 ml) taken for these
assessments.
Study procedures and outcome assessments: 6-month
visit
The 6-month visit will last approximately 3 h, will be
done at the field station and will comprise assessment of
morbidity, anthropometry and nutrition outcome mea-
sures, and administration of the 6-month PZQ or pla-
cebo intervention. Before PZQ/placebo administration,
blood samples (5 ml) will be taken for outcome assess-
ment of complete blood count, with serum used for as-
sessment of morbidity (iron status, EED biomarkers,
measures of inflammation), and stool samples will be
collected for measurement of calprotectin and faecal oc-
cult blood. Children will be weighed and measured, a
clinical history will be taken, and an ultrasound scan will
be performed to determine possible changes compared
to baseline morbidity patterns. Children who were ran-
domly selected at baseline for the assessment of immune
responses to Schistosoma infection and treatment will
have a repeat blood sample (7 ml) taken for these assess-
ments. Following a meal of local foods, children will re-
ceive PZQ/placebo according to the randomisation
allocation, followed by clinical monitoring for post-
treatment adverse events for a 3-h period, as for the
baseline visit, anticipated adverse events will be actively
enquired after and unanticipated adverse events will also
be captured if reported.
Study procedures and outcome assessments: 12-month
visit
The final study visit will take place at the field station,
12 months after enrolment, and will comprise final as-
sessment of morbidity, anthropometry and nutrition
outcome measures. Children will be weighed and mea-
sured, and, for those children whose 6-month ultrasound
scan did not demonstrate resolution of any pathology
detected at baseline, a further ultrasound scan will be
done. Blood samples (5 ml) will be taken for outcome as-
sessment of complete blood count, with serum extracted
for assessment of morbidity (iron status, EED bio-
markers, pro-inflammatory cytokines). Urine samples
will be collected for CAA/CCA. The lactulose:mannitol
test will be repeated using the same procedures as de-
scribed under the enrolment visit. Prior to the visit, field
workers will collect at least two stool samples on con-
secutive days from study participants for Kato-Katz and
for measurement of calprotectin and faecal occult blood.
Children who are still infected with schistosomiasis will
be treated with 40mg/kg PZQ, and children infected
with soil-transmitted helminths will receive albendazole
treatment. Children who were randomly selected at
baseline for the assessment of immune responses to
Schistosoma infection and treatment will have a repeat
blood sample (7 ml) taken for these assessments.
Sample storage and shipment
Samples will be centrifuged and aliquoted into aliquots
at each site and transported from Lake Albert to the
MRC/UVRI and LSHTM Uganda Research Unit in En-
tebbe by road and from Leyte to the Research Institute
for Tropical Medicine in Manilla by air, for storage at −
80 °C in dedicated clinical storage facilities. Further ship-
ments to the USA (serum for markers of EED and iron
status, urine for lactulose-mannitol) and to Liverpool
(serum for pharmacokinetics) for these planned trial
evaluations will be done. Subjects will be asked for per-
mission to keep any samples remaining after the planned
trial evaluations, for possible use in future research stud-
ies. These residual clinical samples will be stored indef-
initely at the clinical storage facilities. Each sample will
be labelled only with a barcode and a unique tracking
number to protect subject confidentiality.
Data management
Socio-demographic information and clinical and labora-
tory measurements will be recorded and managed using
REDCap (Research Electronic Data Capture) tools [28,
29], with paper-based forms as back-up. All data will be
recorded under a unique study ID number. When paper
forms must be used, data will be double entered in a
study-specific database, with standard checks for dis-
crepancies. All data for analysis will be de-identified and
stored on a secure and password-protected server, with
access limited to essential research personnel.
Sample size
We plan to recruit 600 children into the trial, 300 in
Uganda and 300 in the Philippines. The first co-primary
outcome will compare cure rate at 4 weeks in the 300
children who received 80mg/kg PZQ at enrolment com-
pared to the 300 children who received 40mg/kg PZQ
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at enrolment. Data from Uganda estimate cure rates for
S. mansoni infected 3–9 years olds of 70% and 82% for
40 mg/kg and 60 mg/kg PZQ, respectively [17]. Using a
two-sided 5% significance level, approximately 173 chil-
dren per trial arm will be required for 80% power and
232 per arm (N = 464) for 90% power to detect a differ-
ence in cure rate of 70% versus 82% at 4 weeks between
the trial arms. Allowing for loss to follow-up of 7%, a
total of approximately 500 children will be required. A
sample size of 600 will allow us adequate power to
examine sub-groups such as setting/Schistosoma species,
younger (12–30 months) versus older (30–47 months)
children, particularly given that cure rates may be lower
in younger children and the effect size is likely to be lar-
ger based on a higher dose (80 mg/kg).
Statistical analysis
A CONSORT trial flow chart will be constructed, show-
ing the number of children screened, enrolled and ran-
domised, together with reasons for exclusion at each
stage. Baseline characteristics of trial participants will be
summarised by trial arm. Numbers and proportions will
be reported for categorical characteristics. Means, stand-
ard deviations, medians and ranges will be used for con-
tinuous characteristics. All trial analyses will be done
using the intention-to-treat population, i.e. all children
will be included as randomised, regardless of whether or
not they received the allocated treatment. Children will
contribute to 4-week outcomes if they are assessed
within 1 week of the 4-week time point. Children will
contribute to 6- and 12-month outcomes if they are
assessed within 2 weeks of these time points. Loss to
follow-up is expected to be low at 4 weeks since partici-
pants will be visited at their homes; therefore, only chil-
dren for whom outcome data are available will be
included in analyses (complete case analysis), with no
imputation of missing outcome data planned. We will
minimise losses to follow-up for later time points
through continued engagement with the participants
and their communities; field workers will remind partici-
pants of their next follow-up visit and will help with ar-
ranging transportation.
The co-primary outcome of cure rate will be com-
pared between trial arms using a chi-squared test statis-
tic. The difference in proportions cured and a
corresponding 95% confidence interval (CI) will be cal-
culated. For the co-primary outcome of egg reduction
rate, mean egg reduction rate will be compared between
trial arms using a t test, with the difference in mean egg
reduction rate and its 95% confidence interval calculated.
Schistosomal (CCA and CAA) antigenic egg clearance
outcomes will be analysed using the same approach as
for cure rate.
Prevalence of adverse events (both any and separately
for types of event that occur with overall prevalence >
5%) will be compared between trial arms using chi-
squared tests. Rare adverse events will be tabulated by
trial arm but no formal statistical comparisons done. Se-
verity of adverse events will also be tabulated, by trial
arm. Both actively collected information on anticipated
adverse events, and information on spontaneously-
captured unanticipated adverse events will be reported.
For the secondary outcomes assessed at 6 and 12 months
(anthropometry and anaemia), continuous outcomes will
be compared between trial arms using linear regression,
including the corresponding baseline measure as a co-
variate. Binary outcomes assessed at 6 and 12months
will be compared between trial arms using binary/logis-
tic regression, including the corresponding baseline
measure as a covariate. This will be done in order to im-
prove the precision of the treatment effect estimate.
Due to the large sample size, no imbalance is expected
between trial arms. Therefore, no further adjustment for
baseline characteristics is planned for any outcome, un-
less there are significant differences demonstrated at
baseline for key potential confounders. We pre-specify
three key potential effect modifiers to be examined.
These include site (Uganda versus the Philippines), age
(12–30months versus 31–47months) and baseline in-
tensity of infection (low versus moderate/high). We will
examine whether cure rate and egg reduction rate, as
well as key measures of morbidity, differ by these sub-
groups. Effect modification will be tested by fitting inter-
action terms in regression models. Full details of all
planned analyses, including shell tables, will be included
in a formal statistical analysis plan, to be finalised and
reviewed before database lock.
Trial management and data monitoring
A trial steering committee (TSC) and independent data
safety and monitoring board (DSMB) have been estab-
lished. The TSC comprises key study investigators and
independent researchers and stakeholders with expertise
in schistosomiasis, paediatrics, immunology and clinical
trials in low- and middle-income countries. The DSMB
membership comprises expertise in clinical trials, schis-
tosomiasis, paediatrics, and statistics. An independent
clinician with expertise in clinical trials has been
appointed as an independent safety monitor (ISM), and
will review unblinded serious adverse events (SAEs) and
adverse events (AEs) for relatedness to the study
intervention.
The DSMB will provide real-time safety oversight and
may recommend that the investigators place the trial on
hold if deemed necessary. They will have access to un-
blinded data upon request. They will be notified within
7 days of the investigators’ being aware of the occurrence
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of any SAE or any severe AE related to the trial inter-
ventions, or if any of the specified halting rules are met:
 ≥2 SAEs in the first 20 children associated with the
study drug
 ≥5 SAES per 100 children associated with the study
drug
 ≥14 subjects per 100 enrolled experiencing a clinical
AE, that is not listed as expected with treatment,
and that occurs within 2 days after dosing
The DSMB will also provide periodic review of safety
and protocol fidelity and will review the results of an in-
terim analysis to be performed on the primary outcomes
when approximately 20% of children have been rando-
mised and have accrued data on the primary outcomes.
The trial will be monitored by both internal and external
monitors according to a pre-defined monitoring plan
which will include a site initiation visit, monitoring visits
at least annually and a close-out visit. The monitors will
assess patient safety, data integrity and adherence to the
protocol and to Good Clinical Research Practice
procedures.
If it is determined by the site principal investigator or
project leader that an injury occurred to a subject as a
direct result of participation in the trial, then immediate
medical treatment will be provided by the participating
site, with referrals to appropriate health care facilities
provided if necessary. The trial also has insurance in
place to pay for any unexpected, significant adverse
events that are deemed to be due to the study drug.
Dissemination activities
Study findings will be shared with the local community
through community meetings, and with the wider scien-
tific community through open access peer-reviewed pub-
lications, and presentations at local, national and
international conferences. A website describing the PIP
trial has been set up and will be used to share updates
on trial progress and for dissemination of findings [30].
Discussion
The PIP trial will allow us to evaluate optimal treatment
dosing (80 mg/kg versus 40 mg/kg) and optimal intervals
(6 versus 12 months) for intestinal schistosomiasis. We
will assess the impact of these different treatment strat-
egies on key indicators of morbidity that have been im-
plicated in schistosomiasis, yet never previously studied
among children under the age of four. Demonstrating ef-
ficacy with respect to morbidity will support the
prioritization of treatment for this vulnerable age group
and will significantly contribute to the impetus to pro-
vide treatment, even in resource-constrained settings.
One strength of the study design is the assessment of
different doses of PZQ for the two primary species of in-
testinal schistosomiasis, S. mansoni and S. japonicum.
Historically, PZQ dosing for S. japonicum treatment had
been 60 mg/kg, higher than that for S. mansoni and S.
haematobium, based on early efficacy and cure rate
studies [31]. For over three decades, a higher dose of 60
mg/kg was used for S. japonicum. Recently, the WHO
changed dosing recommendations to 40mg/kg for all
species in response to studies demonstrating similar egg
reduction rates and cure rates at 40 and 60mg/kg, how-
ever studies in S. japonicum endemic areas were under-
represented [32] and no studies of children under four
have evaluated this. In addition, no studies have assessed
PK/PD in the context of S. japonicum in children.
Another strength is an examination of the impact of
more frequent dosing on key morbidity outcomes. Chil-
dren in this age group experience high prevalence of an-
aemia, undernutrition, and linear growth faltering. In
areas of high endemicity, they may be rapidly re-
infected, potentially at high intensity. Studies suggest
that even low infections cause morbidity, particularly an-
aemia, such that more frequent treatment of infections
may reduce this risk [33–35]. Furthermore, higher inten-
sity infections have been shown to increase the risk for
morbidity such that more frequent dosing in this vulner-
able age group may have a more significant impact on
morbidity if the intensity of infection is attenuated [36].
In addition, we will capture sophisticated markers of
morbidity, including inflammatory and EED markers.
This will allow us to better understand mechanisms of
morbidity and immune responses to infection in PSAC,
and how they are modified by treatment. Finally, we will
be able to investigate the relationship between EED,
which is known to affect absorptive capacity in the gut,
and PK/PD markers to understand how EED may affect
the absorption of PZQ.
Initial screening activities for the trial commenced in
February 2020; however, following the emergence of the
COVID-19 pandemic and subsequent national lock-
downs, study activities were delayed for approximately 1
year; no participants had been randomised at the time
the trial activities were paused. Screening and enrolment
re-commenced in Uganda in March 2021 and is still
pending in the Philippines. Study limitations include the
use of large tablets that need to be crushed to be given
to this age group. Since one of the main goals of the
study was to inform dosing, a well-characterised dosage
form and vehicle are needed to assess this. It is likely
that these data can be extrapolated to inform dosing if
other formulations such as liquid or oral dispersible tab-
lets are approved. In addition, the use of cut and crushed
tablets leads to imprecise dosing which may make inter-
pretation of PK/PD data difficult. We will minimise this
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risk by using pharmacy grade pill cutters and crushers
that deliver the dose into a small container for
dispersing.
Conclusion
This trial will inform optimal dosing and dosing fre-
quencies for PZQ in this under-studied age group. It will
also quantify and elucidate mechanisms through which
schistosomiasis contributes to linear growth stunting,
anaemia and undernutrition. It is hoped that this will in-
form expansion of mass drug administration programs
to include this vulnerable age group.
Trial status
The current PIP trial protocol is version 3.5 (July 2020).
Trial recruitment is expected to commence in April
2021. We anticipate that recruitment will be completed
in approximately 24 months and that the final follow-up
of an enrolled participant will take place approximately
36 months after the first participant is enrolled.
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